参考文献
[1]Lallemand-Breitenbach V, de Thé H.PML nuclear bodies: from architecture to function[J].Current opinion in cell biology, 2018, 52: 154—161.
[2]Szostecki C, Guldner HH, Netter HJ, et al.Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis[J].The Journal of Immunology, 1990, 145(12): 4338—4347.
[3]Hu SL, Zhao FR, Hu Q, et al.Meta-analysis assessment of GP210 and SP100 for the diagnosis of primary biliary cirrhosis[J].PLoS One, 2014,9(7): e101916.
[4]Szostecki C, Guldner H, Will H.Autoantibodies Against “Nuclear Dots” in Primary Biliary Cirrhosis[J].Seminars in Liver Disease, 1997,17(01): 71—78.
[5]Muratori L, Granito A, Muratori P, et al.Antimitochondrial antibody and other antibody in primary biliary cirrhosis: diagnostic and prognostic value[J].Clinics in liver disease, 2008, 12(2): 261—276.
[6]Mytilinaiou MG, Meyer W, Scheper T, et al.Diagnostic and clinical utility of antibody against the nuclear body promyelocytic leukaemia and Sp100 antigens in patients with primary biliary cirrhosis[J].Clinica Chimica Acta, 2012, 413(15—16): 1211—1216.
[7]Wichmann I, Montes-Cano MA, Respaldiza N, et al.Clinical signif icance of anti-multiple nuclear dots/Sp100 autoantibodies[J].Scandinavian journal of gastroenterology, 2003, 38(9): 996—999.
[8]Bogdanos, DP, Vergani D, Muratori P, et al.Specificity of anti-sp100 antibody for primary biliary cirrhosis[J].Scandinavian Journal of Gastroenterology, 2004, 39(4): 405—406.
[9]Muratori P, Muratori L, Cassani F, et al.Anti-multiple nuclear dots (anti-MND) and anti-SP100 antibody in hepatic and rheumatological disorders[J].Clinical & Experimental Immunology, 2002, 127(1): 172—175.
[10]Zheng B, Mora RA, Fritzler MJ, et al.Establishment of international autoantibody reference standards for the detection of autoantibodies directed against PML bodies, GW bodies, and NuMA protein[J].Clinical Chemistry and Laboratory Medicine (CCLM), 2021, 59(1):197—207.
[11]Ichimura Y, Matsushita T, Hamaguchi Y, et al.Anti-NXP2 autoantibodies in adult patients with idiopathic inf lammatory myopathies: possible association with malignancy[J].Annals of the rheumatic diseases, 2012, 71(5): 710—713.
[12]Ceribelli A, Fredi M, Taraborelli M, et al.Anti-MJ/NXP-2 autoantibody specif icity in a cohort of adult Italian patients with polymyositis/dermatomyositis[J].Arthritis research & therapy, 2012, 14(2): R97.
[13]Tartar D M, Chung L, Fiorentino DF.Clinical significance of autoantibodies in dermatomyositis and systemic sclerosis[J].Clinics in Dermatology, 2018, 36(4): 508—524.
[14]Fujimoto M, Kikuchi K, Tamaki T, et al.Distribution of anti-p80-coilin autoantibody in collagen disease and various skin diseases[J].British Journal of Dermatology, 1997, 137(6): 916—920.
[15]Muro Y.Autoantibodies in atopic dermatitis[J].Journal of dermatological science, 2001, 25(3): 171—178.
[16]Goto N, Sugiura K, Ogawa Y, et al.Anti-p80 coilin autoantibodies react with a conserved epitope and are associated with anti-DFS70/LEDGF autoantibodies[J].Journal of autoimmunity, 2006, 26(1): 42—51.
[17]Chaytow H, Huang YT, Gillingwater TH, et al.The role of survival motor neuron protein (SMN) in protein homeostasis[J].Cellular and Molecular Life Sciences, 2018, 75(21): 3877—3894.
[18]Satoh M, Chan JY, Ross SJ, et al.Autoantibodies to survival of motor neuron complex in patients with polymyositis: immunoprecipitation of D,E, F, and G proteins without other components of small nuclear ribonucleoproteins[J].Arthritis & Rheumatism, 2011, 63(7): 1972—1978.
[19]Amlani A, Hazlewood GS, Hamilton L, et al.Autoantibodies to the survival of motor neuron complex in a patient with necrotizing autoimmune myopathy[J].Rheumatology, 2018, 57(1): 199—200.
[20]Landon-Cardinal O, Baril-Dionne A, Hoa S, et al.Recognising the spectrum of scleromyositis: HEp—2 ANA patterns allow identif ication of a novel clinical subset with anti-SMN autoantibodies[J].RMD open, 2020, 6(2): e001357.